Table 1.
Differences in the clinicopathological characteristics between nodal EBV‐negative and ‐positive CTL
| Nodal EBV‐negative CTL(n = 58) (n [%]) | Nodal EBV‐positive CTL(n = 48) (n [%]) | P | |
|---|---|---|---|
| Age at diagnosis (median[range]) (y) | 65 (29‐88) | 62 (0‐80) | .22 |
| Age at diagnosis > 60 y | 36/58 (62) | 27/48 (56) | .56 |
| Sex (male/female) | 30/28 | 33/15 | .11 |
| PS > 1 | 21/49 (42) | 23/43 (53) | .40 |
| Clinical stage III/IV | 44/57 (77) | 40/46 (86) | .31 |
| B symptoms present | 25/53 (47) | 31/43 (72) | .022 |
| Extranodal site > 1 site | 13/58 (22) | 7/47 (15) | .45 |
| Extranodal sites | |||
| Bone marrow | 11/55 (20) | 11/45 (24) | .63 |
| Liver | 6/58 (10) | 15/46 (32) | .007 |
| Skin and/or soft tissue | 7/58 (12) | 1/46 (2) | .074 |
| GI tract | 3/58 (5) | 1/46 (2) | .63 |
| Hemophagocytosis | 7/51 (13) | 14/40 (35) | .024 |
| IPI_high‐intermediate/high | 34/54 (62) | 29/45 (64) | 1.0 |
| PIT group 3/4 | 38/54 (70) | 30/45 (66) | .83 |
| Hb < 13 g/dL (male) or Hb < 11 g/dL (female) | 25/51 (49) | 23/40 (57) | .53 |
| Platelets < 130 × 109/L | 17/51 (33) | 22/40 (55) | .055 |
| Serum LDH > normal | 42/56 (75) | 35/45 (77) | .81 |
| CRP > normal | 41/48 (85) | 22/25 (88) | 1.0 |
| Prior immunosuppressive drug therapy | 4/47 (8) | 4/25 (16) | .44 |
| History of autoimmune disease | 3/47 (6) | 4/29 (13) | .23 |
| Treatment | |||
| No therapy | 2/58 (3) | 8/45 (17) | .02 |
| CT with anthracycline | 46/55 (83) | 32/45 (71) | .35 |
| CT without anthracycline | 7/55 (12) | 5/45 (11) | 1.0 |
| ASCT | 8/58 (13) | 6/45 (13) | 1.0 |
| Response | |||
| CR | 20/49 (41) | 11/35 (31) | .49 |
| PR | 10/49 (20) | 8/35 (22) | .79 |
| NR | 19/49 (39) | 16/35 (45) | .65 |
| Morphology | |||
| Centroblastoid | 20/50 (40) | 24/46 (52) | .31 |
| Pleomorphic | 14/50 (29) | 12/46 (26) | .91 |
| Mixed | 12/50 (24) | 5/46 (10) | .092 |
| Unspecified | 4/50 (8) | 5/46 (10) | .73 |
| Immunophenotype | |||
| nPD‐L1 | 3/19 (16) | 2/22 (9) | .65 |
| miPD‐L1 | 10/19 (53) | 11/22 (50) | 1.0 |
| TIA‐1 | 50/58 (86) | 46/48 (95) | .11 |
| Granzyme B | 38/55 (69) | 45/47 (95) | <.001 |
| cyCD3 | 49/57 (85) | 46/48 (95) | .11 |
| CD4 | 27/54 (50) | 9/47 (19) | .002 |
| CD5 | 31/55 (56) | 14/47 (29) | .009 |
| CD8 | 14/55 (25) | 30/47 (63) | <.001 |
| CD30 | 24/45 (53) | 12/32 (37) | .25 |
| CD56 | 9/58 (15) | 6/48 (12) | .78 |
ASCT, autologous stem cell transplantation; CR, complete remission; CRP, C‐reactive protein; CT, chemotherapy; CTL, cytotoxic molecule(CM)‐positive peripheral T‐cell lymphoma; cyCD3, cytoplasmic CD3; EBV, Epstein‐Barr virus; GI tract, gastrointestinal tract; Hb, hemoglobin; IPI, International Prognostic Index; LDH, lactate dehydrogenase; miPD‐L1, microenvironmental PD‐L1; nPD‐L1, neoplastic PD‐L1; NR, no response; PIT, prognostic index for PTCL; PR, partial remission; PS, performance status.